NCT02787369View on ClinicalTrials.gov

ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2027

Conditions
Recurrent Chronic Lymphoid Leukemia
Interventions
DRUG

ACY-1215

DRUG

Ibrutinib

DRUG

Idelalisib

Trial Locations (1)

02115

Dana Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
collaborator

Acetylon Pharmaceuticals Incorporated

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER